ライフサイエンスコーパス: N-acetylgalactosamine

1 ctosamine to generate undecaprenyl phosphate-N-acetylgalactosamine.

2 alactose, UDP- N-acetylglucosamine, and UDP- N-acetylgalactosamine.

3 s, characterized by a terminal or sialylated N-acetylgalactosamine.

4 ng glycan ligands that include galactose and N-acetylgalactosamine.

5 three rhamnose residues and a protein-bound N-acetylgalactosamine.

6 ly discriminated for N-acetylglucosamine and N-acetylgalactosamine.

7 ty with regard to both UDP-galactose and UDP-N-acetylgalactosamine.

8 omplete loss of activity with respect to UDP-N-acetylgalactosamine.

9 pecific lectin and shows little affinity for N-acetylgalactosamine.

10 r substrates UDP-N-acetylglucosamine and UDP-N-acetylgalactosamine.

11 glucose, galactose, N-acetylglucosamine and N-acetylgalactosamine.

12 ne-5'-[P1-32P]triphosphate, an analog of UDP-N-acetylgalactosamine.

13 ose and partially reduced with regard to UDP-N-acetylgalactosamine.

14 mino sugars, UDP N-acetylglucosamine and UDP N-acetylgalactosamine.

15 N-acetylglucosamine, mannose, galactose, and N-acetylgalactosamine.

16 eins following binding to terminal galactose/N-acetylgalactosamine.

17 om linking the peptide backbone to the sugar N-acetylgalactosamine.

18 ivatives of 2,4-diacetamidobacillosamine and N-acetylgalactosamine.

19 and was inhibited by N-acetylglucosamine and N-acetylgalactosamine.

20 strate UDP-N-acetylglucosamine or isomer UDP-N-acetylgalactosamine.

21 mg), N-acetylglucosamine (2.27 nmol/mg), and N-acetylgalactosamine (0.652 nmol/mg).

22 epeat unit synthesis, likely by transferring N-acetylgalactosamine-1-P to undecaprenyl-phosphate.

23 Eight N-acetylglucosamine-1-phosphate and N-acetylgalactosamine-1-phosphate analogs have been synt

24 deficient activity of arylsulfatase B (ASB; N-acetylgalactosamine 4-sulfatase) and the subsequent ac

25 iciency of the enzyme arylsulfatase B (ARSB; N-acetylgalactosamine 4-sulfatase), either innate or acq

26 N-acetylglucosamine analog by the epimerase N-acetylgalactosamine-4-epimerase (GALE) like convention

27 ermatan sulfate preparations, we showed that N-acetylgalactosamine-4-O-sulfate residues are required

28 CHST8 encodes a Golgi transmembrane N-acetylgalactosamine-4-O-sulfotransferase (GalNAc4-ST1)

29 dentity with HNK-1 sulfotransferase (21.4%), N-acetylgalactosamine-4-O-sulfotransferase 1 (GalNAc-4-S

30 O-sulfotransferase 1 (GalNAc-4-ST1) (24.7%), N-acetylgalactosamine-4-O-sulfotransferase 2 (GalNAc-4-S

31 We have identified and characterized an N-acetylgalactosamine-4-O-sulfotransferase designated de

32 The sulfatase enzymes, N-acetylgalactosamine-4-sulfatase (arylsulfatase B (ASB)

33 ha-l-iduronidase, iduronate-2-sulfatase, and N-acetylgalactosamine-4-sulfatase that are used for newb

34 ecombinant human (rh) Arylsulfatase B (ARSB; N-acetylgalactosamine-4-sulfatase) markedly reduced the

35 ctivity of the enzyme arylsulfatase B (ARSB; N-acetylgalactosamine-4-sulfatase).

36 Arylsulfatase B (N-acetylgalactosamine-4-sulfatase; ARSB) removes 4-sulfa

37 omal exohydrolase, cleaving sulfate from the N-acetylgalactosamine-4-sulfate (GalNAc-4S) residue at t

38 We have cloned the N-acetylgalactosamine-4-sulfotransferase (GalNAc-4-ST1,

39 cosamine (4FGlcNAc) and UDP-4-deoxy-4-fluoro-N-acetylgalactosamine (4FGalNAc), were prepared using bo

40 actosamine-6-sulfatase (GALNS, also known as N-acetylgalactosamine-6-sulfatase and GalN6S; E.C. 3.1.6

41 is an autosomal recessive disease caused by N-acetylgalactosamine-6-sulfate sulfatase (GALNS) defici

42 oses, including Morquio A syndrome caused by N-acetylgalactosamine-6-sulfate sulfatase (GALNS) defici

43 recessive disorder caused by a deficiency of N-acetylgalactosamine-6-sulfate sulfatase (GALNS), a lys

44 recessive disorder caused by a deficiency of N-acetylgalactosamine-6-sulfate sulfatase (GALNS), leadi

45 ns in the gene encoding the lysosomal enzyme N-acetylgalactosamine-6-sulfate sulfatase (GALNS).

46 age disorder (LSD) caused by a deficiency of N-acetylgalactosamine-6-sulfate sulfatase enzyme.

47 , glucose, 3-deoxy-D-manno-octulosonic acid, N-acetylgalactosamine, 8-epi-legionaminic acid, phosphat

48 consist mostly of core 1 alpha2,6 sialylated N-acetylgalactosamine, a configuration suspected to prev

49 In vivo, AIMers targeted to hepatocytes with N-acetylgalactosamine achieve up to 50% editing with no

50 msen-Friedenreich antigen (galactose beta1-3 N-acetylgalactosamine alpha-), we have found that this l

51 This truncated antigen has the sugar N-acetylgalactosamine alpha-linked to either a serine or

52 t on the presence of multiple O-linked alpha-N-acetylgalactosamine (alpha-GalNAc) determinants.

53 a agglutin (HPA)) with specificity for alpha-N-acetylgalactosamine (alpha-GalNAc), an epitope display

54 r use have been overcome by conjugation with N-acetylgalactosamine, an adduct that targets their deli

55 The sulfate portions of 4-sulfated-N-acetylgalactosamine and an unidentified ligand found i

56 Forssman (Fs) antigen terminates with alpha3-N-acetylgalactosamine and can be used by pathogens as a

57 responsible for the uptake and metabolism of N-acetylgalactosamine and galactosamine in Escherichia c

58 mouse DBP carries a disaccharide composed of N-acetylgalactosamine and galactose.

59 useful for the synthesis of [32P]5-azido-UDP-N-acetylgalactosamine and high-specific-activity [3H] or

60 ally acetylated 1-->4 glycosidic linkages of N-acetylgalactosamine and N-acetylglucosamine.

61 cNAc translocator has lower affinity for UDP-N-acetylgalactosamine and UDP-glucose than for its cogna

62 rmer can catalyze the interconversion of UDP-N-acetylgalactosamine and UDP-N-acetylglucosamine while

63 rpart, mammalian GALE also interconverts UDP-N-acetylgalactosamine and UDP-N-acetylglucosamine.

64 terconverts a larger pair of substrates: UDP-N-acetylgalactosamine and UDP-N-acetylglucosamine.

65 DP-galactose and UDP-glucose, as well as UDP-N-acetylgalactosamine and UDP-N-acetylglucosamine.

66 es l-fucose, d-mannose, N-acetylglucosamine, N-acetylgalactosamine, and galactose).

67 omeric monosaccharides, N-acetylglucosamine, N-acetylgalactosamine, and N-acetylmannosamine.

68 taining the addition of phosphoethanolamine, N-acetylgalactosamine, and N-acetylneuraminic acid.

69 affinity purified on immobilized lactose and N-acetylgalactosamine, and N-glycosylated but not glycos

70 g SQV-7 transported UDP-glucuronic acid, UDP-N-acetylgalactosamine, and UDP-galactose (Gal) in a temp

71 ive form of LD, express a unique glycan with N-acetylgalactosamine as a terminal sugar.

72 -N-acetylglucosamine or uridine 5'-diphospho-N-acetylgalactosamine as substrates but will accept urid

73 However, the enzyme preferentially utilized N-acetylgalactosamine as the donor for all three accepto

74 s that bear uronic acid linked to unsulfated N-acetylgalactosamine as the initial disaccharide in the

75 macrophage activating factor, a protein with N-acetylgalactosamine as the remaining sugar moiety.

76 otein (DBP) to yield the MAF, a protein with N-acetylgalactosamine as the remaining sugar.

77 , including fucose, N-acetylglucosamine, and N-acetylgalactosamine as well as the yeast polysaccharid

78 f Cys-MR alone and complexed with 4-sulfated-N-acetylgalactosamine at 1.7 and 2.2 A resolution, respe

79 Phosphorylated O-mannosyl trisaccharide [N-acetylgalactosamine-beta3-N-acetylglucosamine-beta4-(p

80 gest that it is a good model for the natural N-acetylgalactosamine binding site of the asialoglycopro

81 ca cleaves cell surface galactose-binding or N-acetylgalactosamine-binding (Gal/Gal-NAc) lectins.

82 transferase activity from UDP-galactose onto N-acetylgalactosamine but with a low efficiency.

83 oprotein reporter showed that it transferred N-acetylgalactosamine, but no detectable galactose or N-

84 showed that the purified enzyme transferred N-acetylgalactosamine, but no detectable galactose or N-

85 genes and Streptococcus pneumoniae, and with N-acetylgalactosamine by a Pgf-dependent mechanism in St

86 pwise fashion beginning with the addition of N-acetylgalactosamine by the enzyme N-acetylgalactosamin

87 CRD displays 40-fold preferential binding to N-acetylgalactosamine compared with galactose, making it

88 4-fold increase in the relative affinity for N-acetylgalactosamine compared with galactose.

89 tin family, displays preferential binding to N-acetylgalactosamine compared with galactose.

90 anoparticle formulation or as a triantennary N-acetylgalactosamine conjugate in cells and in mice.

91 /kg or 4 mg/kg RG-101, a hepatocyte targeted N-acetylgalactosamine conjugated anti-miR-122 oligonucle

92 single dose of RG-101, a hepatocyte targeted N-acetylgalactosamine conjugated oligonucleotide that an

93 A fully phosphorothioated, N-acetylgalactosamine-conjugated 16-mer antisense ON (fu

94 Treatment with RG-101, an N-acetylgalactosamine-conjugated anti-microRNA-122 oligo

95 Olezarsen is an N-acetylgalactosamine-conjugated antisense oligonucleoti

96 Cardiovascular outcome trials with N-acetylgalactosamine-conjugated RNA-targeting drugs are

97 hin the guide or passenger strand of the tri-N-acetylgalactosamine-conjugated siRNA targeting mouse T

98 first-in-class, synthetic, double-stranded, N-acetylgalactosamine-conjugated small interfering RNA (

99 Givosiran is a subcutaneously administered N-acetylgalactosamine-conjugated small interfering RNA a

100 as to evaluate the impact of solbinsiran, an N-acetylgalactosamine-conjugated small interfering RNA d

101 taining siRNAs were prepared as triantennary N-acetylgalactosamine conjugates and were tested in cult

102 hyl chemistry and liver targeting enabled by N-acetylgalactosamine conjugation make this ASO highly p

103 d, followed 24 hours later by a biotinylated N-acetylgalactosamine-containing "clearing agent" and fi

104 administered sequentially with a dendrimeric N-acetylgalactosamine-containing clearing agent and radi

105 streptavidin (SA) conjugates, followed by an N-acetylgalactosamine dendrimeric clearing agent and rad

106 oglycan consisting of repeating uronic acid, N-acetylgalactosamine disaccharide units {[HexAbeta/alph

107 ansporter of UDP-N-acetylglucosamine and UDP-N-acetylgalactosamine encoded by the Caenorhabditis eleg

108 of a melittin-derived peptide conjugated to N-acetylgalactosamine for hepatocyte targeting and endos

109 he first enzyme required for biosynthesis of N-acetylgalactosamine, for the major cyst wall polysacch

110 The Fml adhesin FmlH binds galactose beta1-3 N-acetylgalactosamine found in core-1 and -2 O-glycans.

111 ies involving lipid nanoparticle carriers or N-acetylgalactosamine fragments.

112 transfer reaction of N-acetylglucosamine and N-acetylgalactosamine from the respective UDP-sugars to

113 glycans by catalyzing the transfer of alpha-N-acetylgalactosamine from UDP-GalNAc to Ser or Thr resi

114 . parvum sporozoites to the sugar, galactose-N-acetylgalactosamine (Gal/GalNAc), and to bovine mucin

115 The glycan sequence N-acetylgalactosamine, galactose, and sialic acid was co

116 vine DBP carries a trisaccharide composed of N-acetylgalactosamine, galactose, and sialic acid, where

117 O-glycosidase that cleaves galactose beta1-3 N-acetylgalactosamine (Galbeta1-3GalNAc) from core-1 O-l

118 antigen is a disaccharide, galactose beta1-3 N-acetylgalactosamine (Galbeta1-3GalNAc), expressed on t

119 t WbiP could readily glycosylate a series of N-acetylgalactosamine (GalNAc) analogues with alpha-subs

120 produce a polysaccharide capsule containing N-acetylgalactosamine (GalNAc) and beta-3-deoxy-d-manno-

121 hat tx5a contains a disaccharide composed of N-acetylgalactosamine (GalNAc) and galactose (Gal), but

122 r residues: one fucose (Fuc) and two each of N-acetylgalactosamine (GalNAc) and galactose (Gal).

123 ate production of both UDP-galactose and UDP-N-acetylgalactosamine (GalNAc) and is required for the p

124 ge two constituents of cell-surface glycans, N-acetylgalactosamine (GalNAc) and sialic acid, with 10-

125 vine reproductive tract mucins, and terminal N-acetylgalactosamine (GalNAc) and sulfated carbohydrate

126 Chemical analyses confirmed the loss of N-acetylgalactosamine (GalNAc) and the presence of NeuNA

127 all interfering RNAs conjugated to trivalent N-acetylgalactosamine (GalNAc) are clinically validated

128 this protocol, N-acetylglucosamine (GlcNAc)/N-acetylgalactosamine (GalNAc) are phosphorylated by N-a

129 N-Acetylgalactosamine (GalNAc) conjugated short interfer

130 3-independent pathways, and GALNTL5 binds to N-acetylgalactosamine (GalNAc) distributed on the UTJ an

131 aloglycoprotein receptor ligand derived from N-acetylgalactosamine (GalNAc) facilitates targeted deli

132 biosynthesis is initiated by the transfer of N-acetylgalactosamine (GalNAc) from a nucleotide sugar d

133 y occurring glycoconjugate motifs containing N-acetylgalactosamine (GalNAc) from the cheaper and comm

134 ecific for cancer-relevant Ser/Thr(O)-linked N-acetylgalactosamine (GalNAc) glycosylation.

135 omopolymer: chitin in Entamoeba and a unique N-acetylgalactosamine (GalNAc) homopolymer in Giardia.

136 We found that not only galactose but also N-acetylgalactosamine (GalNAc) is an efficient competito

137 nse strand functionalized with the trivalent N-acetylgalactosamine (GalNAc) ligand and cyclized using

138 Ttr) gene and were conjugated to a trivalent N-acetylgalactosamine (GalNAc) ligand for targeted deliv

139 rn and metabolic stability, conjugated to an N-acetylgalactosamine (GalNAc) ligand for targeted deliv

140 id (siRNA) that is conjugated to a trivalent N-acetylgalactosamine (GalNAc) ligand.

141 Tn-antigen (Tn), a single N-acetylgalactosamine (GalNAc) monosaccharide attached t

142 at recognizes the sugars galactose (Gal) and N-acetylgalactosamine (GalNAc) on the surface of host ce

143 es, like FS, catalyze the addition of either N-acetylgalactosamine (GalNAc) or galactose (Gal) in alp

144 a 1-->3 glycosidic linkage to the core alpha-N-acetylgalactosamine (GalNAc) residue.

145 nked to the BclA protein backbone through an N-acetylgalactosamine (GalNAc) residue.

146 taining IgA1 and IgG antibodies specific for N-acetylgalactosamine (GalNAc) residues in O-linked glyc

147 als 61% (range, 12-95%) of the peptide alpha-N-acetylgalactosamine (GalNAc) residues to be substitute

148 t complexed with beta-methyl galactoside and N-acetylgalactosamine (GalNAc) reveal that as with wild-

149 tive transfers of glucoronic acid (GlcA) and N-acetylgalactosamine (GalNAc) to elongate a chain consi

150 -glycosylation by catalyzing the transfer of N-acetylgalactosamine (GalNAc) to Ser or Thr on a protei

151 O glycosylation is initiated by polypeptide N-acetylgalactosamine (GalNAc) transferase (ppGalNAcT) a

152 Our knowledge of the O-glycoproteome [N-acetylgalactosamine (GalNAc) type] is highly limited.

153 aecalibacterium prausnitzii that harbours an N-acetylgalactosamine (GalNAc) utilization gene cluster

154 ine (GlcNAc), galactose (Gal), xylose (Xyl), N-acetylgalactosamine (GalNAc), and glucose (Glc), using

155 ed glycosylation containing galactose (Gal), N-acetylgalactosamine (GalNAc), and sialic acid.

156 minopeptidase N is specifically inhibited by N-acetylgalactosamine (GalNAc), suggesting that this tox

157 ands of small interfering RNA (siRNA) to tri-N-acetylgalactosamine (GalNAc), the ligand for a hepatoc

158 es, as demonstrated by the implementation of N-acetylgalactosamine (GalNAc)-conjugated ASOs for Asial

159 ed silencing in the context of the trivalent N-acetylgalactosamine (GalNAc)-conjugated siRNA in mice

160 One hallmark of trivalent N-acetylgalactosamine (GalNAc)-conjugated siRNAs is the

161 ent with highly potent and durable trivalent N-acetylgalactosamine (GalNAc)-conjugated small interfer

162 n this study, we investigated the effects of N-acetylgalactosamine (GalNAc)-conjugated small interfer

163 Certain lectins recognize the terminal N-acetylgalactosamine (GalNAc)-containing O-glycans on G

164 for facile synthesis of novel and divergent N-acetylgalactosamine (GalNAc)-glycosides and derivative

165 gonucleotide (ASO) and a hepatocyte-specific N-acetylgalactosamine (GalNAc)-modified siRNA, both of w

166 Focusing on liver-targeted N-acetylgalactosamine (GalNAc)-siRNA conjugates, the pri

167 ringiensis strains) lacked Gal and contained N-acetylgalactosamine (GalNAc).

168 arides that are modified with beta1,4-linked N-acetylgalactosamine (GalNAc).

169 -linked galactose and partially deacetylated N-acetylgalactosamine (GalNAc).

170 f mucin O-glycoproteins and their core sugar N-acetylgalactosamine (GalNAc).

171 family of uridine 5'-diphosphate (UDP)-alpha-N-acetylgalactosamine (GalNAc):polypeptide N-acetylgalac

172 proteins bearing terminal galactose (Gal) or N-acetylgalactosamine (GalNAc); however, endogenous liga

173 s containing O-glycans comprised of a single N-acetylgalactosamine (GalNAc, known as Tn antigen) rath

174 Mucin-type (N-acetylgalactosamine [GalNAc]-type) O-glycosylation is

175 A series of sialyl fucosyl poly-N-acetylgalactosamine gangliosides without the sialyl-Le

176 Globoside or P antigen is synthesized by UDP-N-acetylgalactosamine:globotriaosyl-ceramide 3-beta-N-ac

177 ood group criteria and is synthesized by UDP-N-acetylgalactosamine: globotriaosylceramide 3-beta-N-ac

178 -legionaminyltransferase selective for alpha-N-acetylgalactosamine-glycoside (GalNAcalphaOR) acceptor

179 the gene for GM2/GD2 synthase [GalNAcT (UDP-N-acetylgalactosamine:GM3/GD3 beta-1,4-N-acetylgalactosa

180 wth, galactosamine, N-acetylglucosamine, and N-acetylgalactosamine had no significant effect on the p

181 ein, a fourth region likely to interact with N-acetylgalactosamine has been identified and probed by

182 he structural basis for selective binding to N-acetylgalactosamine has been investigated.

183 d to be important in preferential binding to N-acetylgalactosamine have been inserted into the homolo

184 epends on the correct spacer design and that N-acetylgalactosamine improves targeting properties in v

185 s transferred sulfate to the C-4 position of N-acetylgalactosamine in chondroitin and desulfated derm

186 ne a binding pocket for the 2-substituent of N-acetylgalactosamine in the hepatic asialoglycoprotein

187 f HEX-4, there were more glycans capped with N-acetylgalactosamine in the hex-4 mutants, as compared

188 -acetylhexosamine (HexNAc), either GlcNAc or N-acetylgalactosamine, in the terminal position or, alte

189 eglycosylated CD44 enhanced binding; and (d) N-acetylgalactosamine incorporation into non-N-linked gl

190 t is completely inhibited in the presence of N-acetylgalactosamine, indicating loss of domain III bin

191 teins was identified as the 170-kD galactose/N-acetylgalactosamine-inhibitable lectin (Gal/GalNAc) us

192 not galactosamine, N-acetylglucosamine, and N-acetylgalactosamine inhibited the growth of the parasi

193 mediate, and light subunits of the galactose-N-acetylgalactosamine-inhibitible lectin, an important c

194 s changed to valine, loss in selectivity for N-acetylgalactosamine is observed.

195 te residues in combination with 4-O-sulfated N-acetylgalactosamine is sufficient for high affinity bi

196 by yeast hexokinase, homoserine kinase, and N-acetylgalactosamine kinase (obtained by comparison of

197 he transition state were 2.1 x 10(-16) m for N-acetylgalactosamine kinase, 7.4 x 10(-17) m for homose

198 d using 5-azido-UTP, [gamma-32P]ATP, porcine N-acetylgalactosamine kinase, and Escherichia coli UDP-N

199 N-acetylglucosamine and uridine diphosphate N-acetylgalactosamine, leading to the synthesis of epime

200 Fecal anti-galactose/N-acetylgalactosamine lectin immunoglobulin A was associ

201 ed metabolically stable siRNAs combined with N-acetylgalactosamine ligands for conjugate-based liver

202 most adenocarcinomas, Tn antigen, comprising N-acetylgalactosamine linked to serine or threonine, is

203 ducible nitric oxide synthase, and galactose/N-acetylgalactosamine macrophage lectin, as well as TGF-

204 alNAc unit, suggesting that 4-O-sulfation at N-acetylgalactosamine may precede epimerization of glucu

205 initiates docking through recognition of an N-acetylgalactosamine moiety on L. dispar APN.

206 ng galactose, glucose, sialic acid, mannose, N-acetylgalactosamine, N-acetylglucosamine, and fucose.

207 de with the terminal galactose replaced with N-acetylgalactosamine (NHAc-Pk).

208 tylglucosamine (O-GlcNAc) and O-linked alpha-N-acetylgalactosamine (O-GalNAc) (the Tn antigen), in wh

209 O-glycans in the mammalian brain, which are N-acetylgalactosamine (O-GalNAc) linked.

210 ation, O-linked mannose (O-Man) and O-linked N-acetylgalactosamine (O-GalNAc), in its highly conserve

211 Ser/Thr-O-GlcNAc, alpha-linked Ser-O-linked N-acetylgalactosamine (O-GalNAc), or N-linked oligosacch

212 a mucin-related O-linked glycopeptide, alpha-N-acetylgalactosamine-O-serine/threonine (Tn), which is

213 AB interaction enhances the deacetylation of N-acetylgalactosamine oligosaccharides.

214 analogue PPA15(T7), glycosylated with alpha-N-acetylgalactosamine on Thr7, were prepared and investi

215 vent have lost the ability to utilize either N-acetylgalactosamine or galactosamine as sole sources o

216 ers had elevated activity in the presence of N-acetylgalactosamine or galactosamine, were regulated i

217 Enzymatic removal of the terminal N-acetylgalactosamine or galactose of A- or B-antigens,

218 t binds to glycoproteins expressing terminal N-acetylgalactosamine or galactose residues.

219 gens modified with polymeric forms of either N-acetylgalactosamine or N-acetylglucosamine target hepa

220 They usually link to galactose, N-acetylgalactosamine, or other Sia residues, forming li

221 ptor (a structure terminated with galactose, N-acetylgalactosamine, or sialic acid).

222 samine but not by galactose, xylose, fucose, N-acetylgalactosamine, or sialic acid-containing glycopr

223 actions appear to produce the preference for N-acetylgalactosamine over galactose and are also likely

224 e essential for establishing selectivity for N-acetylgalactosamine over galactose.

225 kers, including CWPs and enzymes in the cyst N-acetylgalactosamine pathway.

226 be suppressed by a polymer glycosylated with N-acetylgalactosamine (pGal) and conjugated to the antig

227 the partially deacetylated alpha-1,4 linked N-acetylgalactosamine polymer, Pel.

228 The UDP-N-acetylgalactosamine polypeptide:N-acetylgalactosaminyl

229 by distinct recombinant uridine diphosphate-N-acetylgalactosamine:polypeptide N-acetylgalactosaminyl

230 ptides over Ser peptides for the porcine UDP-N-acetylgalactosamine:polypeptide N-acetylgalactosaminyl

231 the ability to synthesize polyprenyl-phospho-N-acetylgalactosamine (polyprenyl-P-GalNAc) from polypre

232 in complex with the N-acetylglucosamine and N-acetylgalactosamine products of catalysis and in compl

233 cate the existence of another galactose- and N-acetylgalactosamine-recognizing lectin distinct from m

234 isplay stronger binding to galactosamine and N-acetylgalactosamine relative to d-galactose.

235 -linked oligosaccharides containing terminal N-acetylgalactosamine required for [125I]Cry1Ac binding

236 , the core of these glycans is frequently an N-acetylgalactosamine residue that is alpha-linked to se

237 the interaction of the peptide and the first N-acetylgalactosamine residue.

238 l exoglycosidase that cleaves terminal alpha-N-acetylgalactosamine residues from glycopeptides and gl

239 Each cleaved nonreducing alpha(1-->3)-N-acetylgalactosamine residues from human blood group A

240 ient in patients with IgAN, leaving terminal N-acetylgalactosamine residues in the hinge region expos

241 eceptor binds oligosaccharides with terminal N-acetylgalactosamine residues more tightly than ligands

242 on of bulky substituents to the reducing end N-acetylgalactosamine residues of C4S dodecasaccharide h

243 -type lectin 2 receptor on microglia through N-acetylgalactosamine residues, leading to lethal neurod

244 The epitope recognized by 4E9 contains alpha-N-acetylgalactosamine residues, which are present in a m

245 is a result of the presence of alpha-linked N-acetylgalactosamine residues.

246 for determination of the sulfate position on N-acetylgalactosamine residues.

247 their glycan components contain alpha-linked N-acetylgalactosamine residues.

248 bohydrate-recognition domain in complex with N-acetylgalactosamine reveals a direct interaction betwe

249 report that metabolic cross-talk between the N-acetylgalactosamine salvage and O-GlcNAcylation pathwa

250 as good as or better than that of the parent N-acetylgalactosamine, showing that modification on eith

251 N -acetylgalactosamine si Cnnm4 therapy boosts the repai

252 for the rat Kupffer cell lectin (fucose and N-acetylgalactosamine specific) adhered specifically to

253 sferase was significantly lower, and that of N-acetylgalactosamine-specific alpha2,6-sialyltransferas

254 tosyltransferase activity and an increase in N-acetylgalactosamine-specific alpha2,6-sialyltransferas

255 yltransferase or a terminal sialic acid by a N-acetylgalactosamine-specific alpha2,6-sialyltransferas

256 known as the mouse macrophage galactose- and N-acetylgalactosamine-specific lectin (mMGL).

257 either patent or latent reactivity with the N-acetylgalactosamine-specific lectin Vicia villosa aggl

258 the neutralizing effect of the MAb and alpha-N-acetylgalactosamine-specific lectins strongly implicat

259 hydrate units that terminate with a sulfated N-acetylgalactosamine structure (GalNAc-4-SO(4)) that me

260 ecific for either N-acetylneuraminic acid or N-acetylgalactosamine, suggesting that it was composed o

261 oglycan consisting of repeating uronic acid, N-acetylgalactosamine sulfate disaccharide units [-UroA(

262 ctrophoresis analysis demonstrated increased N-acetylgalactosamine sulfation at both 4- and 6-carbons

263 lectins specifically recognize galactose- or N-acetylgalactosamine-terminated oligosaccharides.

264 ystal structure of the modified CRD bound to N-acetylgalactosamine, the histidine (His(202)) contacts

265 for the discrimination between galactose and N-acetylgalactosamine, the substrate transferred by GTA.

266 lls convert added peracetylated benzyl-alpha-N-acetylgalactosamine to a large variety of modified O-g

267 nkages joining either N-acetylglucosamine or N-acetylgalactosamine to a wide variety of aglycon resid

268 se structures showed N-acetylglucosamine and N-acetylgalactosamine to be recognized via identical set

269 nsferred galactose, N-acetylglucosamine, and N-acetylgalactosamine to carbohydrate, glycoprotein, and

270 ndensation of undecaprenyl phosphate and UDP-N-acetylgalactosamine to generate undecaprenyl phosphate

271 arabinose, fucose, methyl galacturonate and N-acetylgalactosamine to give the corresponding peracety

272 binant EXTL2 showed weak ability to transfer N-acetylgalactosamine to heparan sulfate precursor molec

273 were chemically stabilized and conjugated to N-acetylgalactosamine to increase liver uptake.

274 modification of glycans by beta4 addition of N-acetylgalactosamine to N-acetylglucosamine with format

275 tro incorporation of N-acetylglucosamine and N-acetylgalactosamine to oligosaccharide acceptors resem

276 gainst Anln messenger RNA were conjugated to N-acetylgalactosamine to reduce toxicity and increase he

277 The addition of N-acetylgalactosamine to Ser71, Thr72, Thr75, and Thr139

278 BZU3 also catalyzes the epimerization of UDP-N-acetylgalactosamine to UDP-N-acetylglucosamine, and th

279 the acetyl group from undecaprenyl phosphate-N-acetylgalactosamine to yield undecaprenyl phosphate-be

280 synthase K4CP catalyzes glucuronic acid and N-acetylgalactosamine transfer activities and polymerize

281 r sequence abolishes glucuronic acid but not N-acetylgalactosamine transfer activity in K4CP.

282 The polypeptide N-acetylgalactosamine transferase-1 (ppGalNAcT-1) initia

283 oplasmic reticulum relocation of polypeptide N-acetylgalactosamine-transferases (GalNAc-Ts) drives hi

284 nd purified the rat liver Golgi membrane UDP-N-acetylgalactosamine transporter.

285 We conjugated binders to a triantenerrary N-acetylgalactosamine (tri-GalNAc) motif that engages AS

286 Here we show that the N-acetylgalactosamine-type O-glycosylation enzyme GALNT1

287 otein, shows UDP-GlcNAcA 4-epimerase and UDP-N-acetylgalactosamine (UDP-GalNAc) 4-epimerase activitie

288 UDP-N-acetylglucosamine (UDP-GlcNAc) and UDP-N-acetylgalactosamine (UDP-GalNAc) transport in Arabidop

289 0 ratio of UDP-GlcNAc to uridine diphosphate-N-acetylgalactosamine (UDP-GalNAc), irrespective of the

290 s to complex gangliosides bearing the sialyl N-acetylgalactosamine unit.

291 d-type transporter, whereas transport of UDP-N-acetylgalactosamine was decreased by 85-90%, resulting

292 VPTTST(GalNAc)TSAP (where GalNAc is O-linked N-acetylgalactosamine), were shown to coelute following

293 es, composed mainly of galacturonic acid and N-acetylgalactosamine, were characterised for the first

294 ased on these results and the orientation of N-acetylgalactosamine when bound to an homologous galact

295 -2, however, did not form 4, 6-di-O-sulfated N-acetylgalactosamine when chondroitin sulfate C was use

296 d on Thr(402) with an N-acetylglucosamine or N-acetylgalactosamine, whereas Ser(692) remained unmodif

297 G), which inhibit membrane interactions, and N-acetylgalactosamine, which targets asialoglycoprotein

298 tered O-glycans consisting of Ser/Thr-linked N-acetylgalactosamine with beta1,3-linked galactose and

299 with UDP-glucose and interconversion of UDP-N-acetylgalactosamine with UDP-N-acetylglucosamine.

300 N-Acetylgalactosamine yielded two major peaks, which wer